Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jul 02, 2026
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results)
TOKYO, July 2, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release on July 2, regarding the results of the global Phase III clinical trial (Krascendo1) evaluating the KRAS G12C inhibitor divarasib in previously treated KRAS G12C-positive non-small cell lung cancer.
The detailed data will be presented at an upcoming medical meeting.
Please refer to the link below for details of the media release:
Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Naoki Kozai
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp